News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
DGAP-News: Eckert & Ziegler to Open up US-Production Site for Yttrium-90
DGAP-News: Eckert & Ziegler to Open up US-Production Site for Yttrium-90
DGAP-News: Eckert & Ziegler to Open up US-Production Site for Yttrium-90
DGAP-News: Eckert & Ziegler to Open up US-Production Site for Yttrium-90
DGAP-News: MorphoSys Initiiert Expanded Access Program für Tafasitamab in den USA
DGAP-News: MorphoSys Initiiert Expanded Access Program für Tafasitamab in den USA
DGAP-News: MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
DGAP-News: MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
DGAP-News: MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
DGAP-News: MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
DGAP-News: MorphoSys Initiiert Expanded Access Program für Tafasitamab in den USA
DGAP-News: MorphoSys Initiiert Expanded Access Program für Tafasitamab in den USA
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
DGAP-News: EVOTEC AND BAYER ADVANCE FURTHER PROGRAMME INTO PHASE I CLINICAL DEVELOPMENT
DGAP-News: EVOTEC AND BAYER ADVANCE FURTHER PROGRAMME INTO PHASE I CLINICAL DEVELOPMENT
DGAP-News: EVOTEC UND BAYER ÜBERFÜHREN WEITERES PROGRAMM IN KLINISCHE PHASE-I-STUDIE
DGAP-News: EVOTEC UND BAYER ÜBERFÜHREN WEITERES PROGRAMM IN KLINISCHE PHASE-I-STUDIE